EGFR-Mutated Lung Cancer Perspectives

David P. Carbone, MD, PhD, professor of medicine at The Ohio State University Comprehensive Cancer Center, Barbara J. Bonner Chair in Lung Cancer Research and director of the James Thoracic Center, spoke with Healio about managing patients with EGFR-mutated lung cancer.

In this video, Carbone discusses:

• his experience with new first-line therapy for EGFR-mutated lung cancer;
• concerns about resistance to tyrosine kinase inhibitors;
• the role of chemotherapy since the emergence of targeted therapy;
• early but “promising” results of a four-drug regimen combining chemotherapy, immunotherapy and antiangiogenic therapy; and
• other new agents in the pipeline.